Liposomes for Therapeutics

The blood-brain barrier (BBB) protects the brain from potentially harmful substances and limits drug delivery to the central nervous system (CNS). The existence of BBB limits therapeutic accessibility to the brain, making it difficult to discover new approaches to treating brain disorders.

Fig 1. Drug transport mechanism of liposomes in BBB.

Liposomes have been employed as drug carriers for BBB penetration due to their biocompatibility. It can transport drugs from the apical to the basolateral plasma membrane of the BBB. This is achieved through carrier-mediated transcytosis (CMT), receptor-mediated transcytosis (RMT) and adsorptive mediated transcytosis (AMT).

Additionally, we can offer liposome-assisted intranasal drug-carrying systems to address the problem of insufficient drug concentration in the brain due to BBB. This strategy triggers nose-to-brain delivery via olfactory nerve stimulation, increasing drug absorption in the brain.

Liposomes can be used as drug delivery carriers for heart diseases. We can meet your needs for the treatment of cardiovascular diseases such as myocardial infarction, ischemic injury, heart failure, coronary artery disease, arrhythmia, cardiomyopathy, congenital heart disease, and others by providing you with magnetic liposomes, cationic liposomes, and modified liposomes.

Liposomes can be targeted to areas where the reticuloendothelial system is abundant, such as the lungs. By adjusting the particle size, potential, and modification of liposomes, we can provide you with solutions for the treatment of lung diseases such as asthma, tuberculosis, emphysema, cystic fibrosis, and lung cancer.

The barrier function of the epidermis makes it difficult for drugs to penetrate deeper into the skin. As a preferred strategy in the treatment of dermatology, liposomes allow encapsulated drugs to cross the skin barrier and improve their permeability to the dermis and epidermis. By adjusting the composition, structure, surface charge and size of liposomes, we can provide you with better transdermal effects including Transferosomes, Ethosomes, Marinosomes, etc.

Bone regeneration is a therapeutic process in which liposomes and biomaterials can effectively work together to repair bones, thereby reducing bone implantation. Through the macrophages, paracellular pathways, and transcellular pathways, liposomes can deliver encapsulated drugs to the bone-defected area by way of the bloodstream.

Anthraquinones such as daunorubicin are used to treat blood disorders with a short plasma half-life. However, these drugs are prone to resistance and cross-resistance with damage to the immune system. We can develop related liposomes to extend their plasma half-life while reversing cross-resistance for your therapeutic needs in leukemia, anemia and other blood disorders.